- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03670446
Pharmacists' Intervention in Patients Using Novel Oral Anticoagulants:A Study on Behavioral Patterns
Novel oral anticoagulant drugs (NOACs) are now increasingly used in clinical practice. Although there are outstanding advantages of NOACs, there are also some shortcomings in use. The behavioral pattern of patients using novel oral anticoagulant drugs can directly affect the effect of anticoagulant therapy.
However, at present, there is no study on behavioral patterns of compliance and cognition in patients using NOACs in China. There are few reports on the management outcomes of NOACs anticoagulant therapy as well. Above all, exploring whether pharmacists change behavioral patterns in patients using NOACs is of great significance to improve the effectiveness and safety and to prove the value of pharmacists who provide pharmaceutical care.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a prospective randomized controlled trial. Patients who will use NOACs are prospectively divided into routine group and pharmacist intervention group.
For the intervention group, pharmacists regularly provide telephone and outpatient follow-up combined with patient medication education, establishing database system, telephone reminder, etc. At the 12-week follow-up, behavioral patterns of compliance, self-anxiety, depression status and satisfaction with the pharmacist service will be evaluated in both groups. Pharmacodynamic substitution indicators and endpoints will be collected as well.
Clinical data is designed to be collected from 400 patients, 200 patients each group. Data will be recorded by Epidata dual-track, analyzed by SPSS19.0 software. P<0.05 is considered significant.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100034
- Recruiting
- Peking University First Hospital
-
Contact:
- Qian Xiang, Ph.D
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- China Rehabilitation Research Center Beijing Boai Hospital
-
Contact:
- Wen Li, M.S
- Email: crrc_lw@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients or inpatients with anticoagulation indications of novel oral anticoagulant drugs (NOACs).
- New prescriptions for NOACs, or previous prescriptions for NOACs, not received any intervention by pharmacists before.
- Written informed consent was obtained from patients or their families.
Exclusion Criteria:
- Patients who did not use novel oral anticoagulants.
- Patients who had received interventions from pharmacists, such as medication education.
- Written informed consent was not obtained from patients or their families.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmacists' intervention
A group of participants assigned to a pharmaceutical intervention
|
|
No Intervention: Routine therapy
A group of participants assigned to a control (routine therapy)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication adherence
Time Frame: 12 weeks
|
The Morisky, Green, and Levine Adherence Scale (MGLS) was used to evaluate the medication compliance of dabigatran etexilate and rivaroxaban during treatment.
According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
|
12 weeks
|
Mental status
Time Frame: 12 weeks
|
Mental status is assessed by Self-rating Depression Scale (SDS) and Self-rating Anxiety Scale (SAS). The threshold value of depression assessment was 53, the higher the score, the more obvious the tendency of depression. 53-62 is defined as mild depression, 63-72 for moderate depression, 72 points above for severe depression. The standard score of SAS was 50, of which 50-59 is mild anxiety, 60-69 is moderate anxiety and 69 is severe anxiety. The patient's awareness of medication is assessed by a self-designed awareness questionnaire. |
12 weeks
|
anti-Xa and IIa activities
Time Frame: 12 weeks
|
Anti-Xa/IIa activity test is divided into peak concentration and valley concentration detection; peak concentration is 100 ng/ml as the critical value, Valley concentration is 50 ng/ml as the limit, divided into better or poor pharmacodynamic indicators.
patients with peak concentration > 100 ng/ml or valley concentration > 50 ng/ml are defined as better pharmacodynamic indicators.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018[173]
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Behavioral Symptoms
-
AccareRecruitingBehavioral Problem of Child | Behavioral DifficultiesNetherlands
-
University of AarhusInnovation Fund Denmark; TRYG Foundation; The Danish Mental Health Foundation; Aarhus...CompletedDepressive Symptoms | Anxiety Symptoms | Behavioral Problem | School AbsenteeismDenmark
-
Universidade do PortoCentro Hospitalar Universitário de São João, E.P.E.; Centro de Investigação... and other collaboratorsCompletedAnxiety | Behavioral Problem of ChildPortugal
-
Central Hospital, Nancy, FranceMarie MANGEOT- Nurse; Mahmut GUNDESLI MDCompleted
-
AccareRecruitingBrief Parent Training for Children With Behavioral Difficulties in Primary Care Settings (PAINT-POH)Behavioral DifficultiesNetherlands
-
Fatima Jinnah Women UniversityRecruitingWell-being, Emotional and Behavioral Problems, AdolescentsPakistan
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanCompleted
-
AccareRecruitingBehavioral Symptoms | Behavior Problems | Behavioral Problems | Disruptive Behavior | Problem Behaviors | Behavioral DifficultiesNetherlands
-
University of California, San FranciscoCompleted
-
New York State Psychiatric InstituteSackler FoundationTerminated
Clinical Trials on Pharmacists' intervention
-
Providence VA Medical CenterLifespan; University of Rhode IslandRecruiting
-
RenJi HospitalCompletedRheumatic DiseasesChina
-
University of JordanCompleted
-
Randers Regional HospitalAarhus University HospitalCompleted
-
Virginia Commonwealth UniversityCompleted
-
Peking University Third HospitalUnknown
-
Memorial University of NewfoundlandCompleted
-
Shaoxing Maternity and Child Health Care HospitalCompletedPreterm Infants | Pharmaceutical Care | Clinical OutcomeChina
-
University of New MexicoCompletedContraceptionUnited States
-
Hospital Pharmacy of North Norway TrustUniversity Hospital of North Norway; University of Tromso; Nordlandssykehuset HF and other collaboratorsActive, not recruitingEmergency Department | Clinical PharmacistNorway